Britain and America have established a significant bilateral deal that will keep zero import taxes on UK pharmaceutical exports entering the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase funding on medicines through the NHS. This move ensures that tariffs on these vital exports will be held at nothing for a timeframe of three years.
This development follows previous statements to dramatically increase import taxes on patented pharmaceutical products, with increases discussed reaching double the cost.
"This arrangement between the United Kingdom reinforces the worldwide climate for cutting-edge drugs and introduces much-needed equity to transatlantic medicine commerce," a release said.
Trade Impact
Pharmaceuticals constitute one of the Britain's largest goods shipped to the America, which is by far the primary destination for large companies like GSK and AstraZeneca.
Export figures reveal that in the year to the end of September, the UK sold drugs worth £11.1bn to the US. This amount made up nearly one-fifth of all goods exports in that period.
"This agreement safeguards jobs, increases investment and paves the way for the UK to emerge as a international leader for biotech and pharma," a government official commented.
Specific NHS Changes
The agreement entails several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to increase total health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must return to the NHS to control costs will be capped at fifteen percent. In the past, refunds were more than 20%.
Broader Context
The deal comes amid a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were heightened by arguments that American customers were paying several times more for the same drugs than people in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been pledged toward American operations.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its expenditure on drugs had declined as a proportion of its resources over the previous ten-year period.
